Back to Search Start Over

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated by chemotherapy for solid cancers

Authors :
J. Barrière
Marianne Veyri
P. Maingon
Marc-Antoine Benderra
Romain Palich
J-P. Spano
Z. Adjoutah
Laurence Morand-Joubert
A G Marcelin
Stéphane Marot
Joseph Gligorov
Aurore Vozy
Service d'Oncologie médicale [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP)
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut Universitaire de Cancérologie [Paris] (IUC)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Service de virologie [CHU Pitié-Salpêtrière]
Service d'Oncologie médicale [CHU Tenon]
CHU Tenon [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Service d'Oncologie Radiothérapie [CHU Pitié Salpétrière]
Laboratoire de Virologie [CHU Saint-Antoine]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
Cerballiance
HAL-SU, Gestionnaire
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Service de Virologie [CHU Pitié-Salpêtrière]
Source :
Annals of Oncology, Annals of Oncology, Elsevier, In press, ⟨10.1016/j.annonc.2021.06.018⟩, Annals of Oncology, In press, ⟨10.1016/j.annonc.2021.06.018⟩
Publication Year :
2021
Publisher :
Published by Elsevier Ltd on behalf of European Society for Medical Oncology., 2021.

Abstract

International audience

Subjects

Subjects :
COVID-19 Vaccines
medicine.medical_treatment
[SDV.CAN]Life Sciences [q-bio]/Cancer
03 medical and health sciences
0302 clinical medicine
[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology
[SDV.CAN] Life Sciences [q-bio]/Cancer
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Neoplasms
medicine
Humans
In patient
Seroconversion
Letter to the Editor
BNT162 Vaccine
ComputingMilieux_MISCELLANEOUS
030304 developmental biology
Cancer
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases
0303 health sciences
Chemotherapy
Vaccines
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases
business.industry
SARS-CoV-2
Vaccination
Antibody titer
COVID-19
Hematology
3. Good health
mRNA vaccine
Serology
Oncology
030220 oncology & carcinogenesis
Immunology
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
business

Details

Language :
English
ISSN :
15698041 and 09237534
Database :
OpenAIRE
Journal :
Annals of Oncology
Accession number :
edsair.doi.dedup.....a88fef4d2bc71d6cca59b3d27e435f98
Full Text :
https://doi.org/10.1016/j.annonc.2021.06.018⟩
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details